X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse SHASUN PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SHASUN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
SHASUN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs94353-   
Low Rs46255-   
Sales per share (Unadj.) Rs214.2105.0-  
Earnings per share (Unadj.) Rs5.3-26.5-  
Cash flow per share (Unadj.) Rs15.8-21.9-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.382.4-  
Shares outstanding (eoy) m56.62168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 11.3%   
Avg P/E ratio x13.1-11.5 -114.1%  
P/CF ratio (eoy) x4.4-13.9 -31.9%  
Price / Book Value ratio x1.33.7 35.5%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,95851,290 7.7%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m2,1643,219 67.2%   
Avg. sales/employee Rs ThNM4,129.2-  
Avg. wages/employee Rs ThNM749.8-  
Avg. net profit/employee Rs ThNM-1,040.5-  
INCOME DATA
Net Sales Rs m12,12717,727 68.4%  
Other income Rs m229124 184.8%   
Total revenues Rs m12,35617,851 69.2%   
Gross profit Rs m1,009-3,072 -32.8%  
Depreciation Rs m594765 77.6%   
Interest Rs m415480 86.4%   
Profit before tax Rs m230-4,193 -5.5%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73262 -27.8%   
Profit after tax Rs m302-4,467 -6.8%  
Gross profit margin %8.3-17.3 -48.0%  
Effective tax rate %-31.7-6.2 506.7%   
Net profit margin %2.5-25.2 -9.9%  
BALANCE SHEET DATA
Current assets Rs m6,88412,983 53.0%   
Current liabilities Rs m8,4567,305 115.8%   
Net working cap to sales %-13.032.0 -40.5%  
Current ratio x0.81.8 45.8%  
Inventory Days Days62111 55.6%  
Debtors Days Days108124 86.8%  
Net fixed assets Rs m4,9707,568 65.7%   
Share capital Rs m11382 137.7%   
"Free" reserves Rs m2,8750-   
Net worth Rs m3,02013,914 21.7%   
Long term debt Rs m1,8174,889 37.2%   
Total assets Rs m13,34726,284 50.8%  
Interest coverage x1.6-7.7 -20.1%   
Debt to equity ratio x0.60.4 171.2%  
Sales to assets ratio x0.90.7 134.7%   
Return on assets %5.4-15.2 -35.4%  
Return on equity %10.0-32.1 -31.2%  
Return on capital %13.3-19.8 -67.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Net fx Rs m3,6690-   
CASH FLOW
From Operations Rs m3981,513 26.3%  
From Investments Rs m-1,635-465 351.9%  
From Financial Activity Rs m1,3094,438 29.5%  
Net Cashflow Rs m715,486 1.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.87 Rs / ZAR

Compare SHASUN PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SHASUN PHARMA With: STERLING BIOTECH  PIRAMAL ENTERPRISES  GLENMARK PHARMA  PANACEA BIOTECH  TTK HEALTHCARE  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - PANACEA BIOTECH COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS